Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.

AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...

AstraZeneca PLC AZN shares rallied 1.33% to £117.20 Thursday, on what proved to be an all-around great trading session for ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...

The AstraZeneca PLC ADR AZN slumped 0.35% to $76.87 Tuesday, on what proved to be an all-around favorable trading session for ...

The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...